Sol-Gel Technologies Cash Flow from Investing Activities 2016-2023 | SLGL
Sol-Gel Technologies cash flow from investing activities from 2016 to 2023. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
Sol-Gel Technologies Annual Cash Flow Investing
(Millions of US $) |
| 2023 |
$-10 |
| 2022 |
$2 |
| 2021 |
$20 |
| 2020 |
$-3 |
| 2019 |
$16 |
| 2018 |
$-55 |
| 2017 |
$-6 |
| 2016 |
$-0 |
| 2015 |
$-0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.019B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
